Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Decline in Short Interest

Monopar Therapeutics Inc. (NASDAQ:MNPRGet Rating) was the recipient of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 2,900 shares, a drop of 55.4% from the March 31st total of 6,500 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily trading volume, of 5,800 shares, the days-to-cover ratio is presently 0.5 days.

An institutional investor recently raised its position in Monopar Therapeutics stock. Geode Capital Management LLC raised its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPRGet Rating) by 36.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,171 shares of the company’s stock after buying an additional 10,410 shares during the quarter. Geode Capital Management LLC owned about 0.31% of Monopar Therapeutics worth $189,000 as of its most recent SEC filing. 1.57% of the stock is currently owned by institutional investors.

MNPR traded down $0.02 on Friday, hitting $2.28. 16,434 shares of the company’s stock traded hands, compared to its average volume of 2,115. The company’s 50 day simple moving average is $2.73 and its 200-day simple moving average is $3.47. Monopar Therapeutics has a one year low of $2.14 and a one year high of $6.98.

Monopar Therapeutics (NASDAQ:MNPRGet Rating) last issued its earnings results on Thursday, March 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Equities research analysts predict that Monopar Therapeutics will post -1.01 earnings per share for the current year.

Several research analysts have recently commented on MNPR shares. Zacks Investment Research raised Monopar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 18th. Roth Capital reaffirmed a “buy” rating on shares of Monopar Therapeutics in a research note on Thursday, March 24th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Monopar Therapeutics in a research note on Friday, March 25th.

Monopar Therapeutics Company Profile (Get Rating)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Read More

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with's FREE daily email newsletter.